Successful treatment of cerebral vasculitis in an HIV-positive patient with anti-CD25 treatment
Authors:
- C M G NieuwhofCNC M G Nieuwhof
- J DamoiseauxJDJ Damoiseaux
- J W Cohen TervaertJTJ W Cohen Tervaert
- 1 December 2006
- journal article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 65 (12) , 1677-1678
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- A novel therapeutic option in pemphigus vulgaris: humanized monoclonal anti-CD25 antibodyBritish Journal of Dermatology, 2004
- Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon βProceedings of the National Academy of Sciences, 2004
- Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administrationJournal of Autoimmunity, 2003
- Reconstitution of CD4+ T cell responses in HIV-1 infected individuals initiating highly active antiretroviral therapy (HAART) is associated with renewed interleukin-2 production and responsivenessClinical and Experimental Immunology, 2003
- A pilot study on the use of the humanized anti–interleukin-2 receptor antibody daclizumab in active ulcerative colitisAmerican Journal of Gastroenterology, 2003
- A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitisAmerican Journal of Gastroenterology, 2003
- Cerebral vasculitis after initiation antiretroviral therapyAIDS, 2002
- α‐CD25 antibody treatment in a child with hemophagocytic lymphohistiocytosisMedical and Pediatric Oncology, 2002
- Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease.2000
- Primary (granulomatous) angiitis of the central nervous system: A clinicopathologic analysis of 15 new cases and a review of the literatureHuman Pathology, 1992